Dermatology Department, Johns Hopkins University, Baltimore, MD, USA.
Photodermatol Photoimmunol Photomed. 2014 Feb;30(1):3-7. doi: 10.1111/phpp.12088. Epub 2013 Dec 3.
Over 10 years have passed since the first approval of a biologic agent for the treatment of psoriasis. No one can argue that the arrival of this entirely new, highly effective class of medications has not forever changed the therapeutic landscape for psoriasis. Traditional treatments such as phototherapy, however, remain both viable and effective therapies, both as standalone treatments and in combination with biologics. In general, synergistic effects are noted for combinations utilizing phototherapy; however, the long-term impact of these combinations on skin cancer development has yet to be fully determined. Increasing financial pressures for cost-effective therapies augment the appeal of phototherapy and other traditional treatments as compared with the more costly biologics. Phototherapy also remains strong outside the realm of psoriasis, in the management of atopic dermatitis, vitiligo, and cutaneous T-cell lymphoma, among other conditions. Phototherapy will remain a cornerstone in the management of psoriasis as well as nonpsoriatic skin conditions, as its efficacy is well known, its financial cost is reasonable, it is readily compatible with other therapeutics, and its utility is historically proven.
自首个生物制剂获批用于治疗银屑病以来，已经过去了 10 多年。没有人能否认，这种全新的、高效的药物类别彻底改变了银屑病的治疗格局。然而，光疗等传统疗法仍然是可行且有效的治疗方法，无论是作为单一疗法还是与生物制剂联合使用。一般来说，联合使用光疗会产生协同作用；然而，这些联合治疗对皮肤癌发展的长期影响尚未完全确定。为了寻求更具成本效益的治疗方法，不断增加的财务压力增加了光疗和其他传统治疗方法的吸引力，而这些方法比更昂贵的生物制剂更具成本效益。光疗在银屑病领域之外也很强大，可用于治疗特应性皮炎、白癜风和皮肤 T 细胞淋巴瘤等疾病。光疗将继续成为治疗银屑病和非银屑病性皮肤疾病的基石，因为其疗效众所周知，其财务成本合理，与其他疗法兼容，并且其效用具有历史证明。
